CS
FOLD

Credit Suisse’s Amicus Therapeutics FOLD Stock Holding History

Credit Suisse’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-278,100
Closed -$4.18M – 4028
2018
Q1 		$4.18M Sell
278,100
-1,049,700
-79% -$16M ﹤0.01% 1838
2017
Q4 		$19.1M Buy
1,327,800
+352,800
+36% +$4.85M 0.02% 901
2017
Q3 		$14.7M Buy
+975,000
New +$12.9M 0.01% 1018

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse's FOLD Position: Q1 2024 in Review

Credit Suisse reduced its Amicus Therapeutics (FOLD) stake by 1.1% in Q1 2024, selling an estimated $47K and leaving 322,544 shares worth $3.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Credit Suisse first reported a position in FOLD in Q2 2013 and has held it in 44 quarters since. The position peaked at $13.8M in Q3 2017. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Credit Suisse held 322,544 shares of Amicus Therapeutics worth $3.8M as of Q1 2024.
  • Credit Suisse sold 3,673 Amicus Therapeutics shares in Q1 2024, an estimated $47K.
  • Amicus Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1458 holding.
  • Credit Suisse first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Amicus Therapeutics position peaked at $13.8M in Q3 2017.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.